-
team members
worldwide -
countries
served -
dose manufacturing
capacity -
pharmaceutical &
consumer health products -
years and
counting
.webp?sfvrsn=2eb9a573_2)
-(1).webp?sfvrsn=365b9248_1)
Latest news
-
Feb 5, 2026
Apotex licenses exclusive Canadian rights to testosterone replacement therapy Nebido® from Grünenthal
Toronto, Canada, & Aachen, Germany – February 5, 2026 – Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).
-
Nov 17, 2025
Apotex donation helps Oak Valley Health respond to urgent capacity needs amid rapid community growth
MARKHAM, ON - As Markham and the surrounding region experience rapid population growth, Oak Valley Health's Markham Stouffville Hospital (MSH) is taking steps to expand capacity and improve access to care — thanks to a gift from Apotex Inc., the Canadian-based global health company.
-
Oct 23, 2025
Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Toronto, ON - October 23, 2025 - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI® (toripalimab) for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer.
